Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 5,860.00
+40.00 (0.69%)
At close: Sep 22, 2026
Prestige BioPharma Revenue
Prestige BioPharma had revenue of 509.20M KRW in the quarter ending March 31, 2026, a decrease of -84.75%. This brings the company's revenue in the last twelve months to 16.21B, up 87.13% year-over-year. In the fiscal year ending June 30, 2025, Prestige BioPharma had annual revenue of 14.33B with 1,978.97% growth.
Revenue (ttm)
16.21B
Revenue Growth
+87.13%
P/S Ratio
4.35
Revenue / Employee
253.28M
Employees
64
Market Cap
70.43B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 14.33B | 13.64B | 1,978.97% |
| Jun 30, 2024 | 689.08M | 527.23M | 325.77% |
| Jun 30, 2023 | 161.84M | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ORIENT BIO | 59.09B |
| Amicogen | 46.69B |
| GeneOne Life Science | 12.37B |
| Genexine | 5.81B |
| iNtRON Biotechnology | 5.74B |
| IMB Dx | 5.60B |
| MedPacto | 4.99B |
| ENCell | 4.16B |